Physician profile
Jason Lowe
NPI 1669588802
$269,869.97
in general payments reported to CMS, 2019-2025
7 companies · $125K in 2025
The $125K reported for 2025 was more than what 96% of Orthopaedic Trauma providers received nationally (typical 2025 total: $1,227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $12K · 2021: $44K · 2022: $27K · 2023: $21K · 2024: $9,668 · 2025: $125K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $116K · Consulting Fee: $19K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $12K · Travel and Lodging: $7,278 · Food and Beverage: $2,110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $116,232.45 |
| Consulting Fee | $18,857.83 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $11,500.00 |
| Travel and Lodging | $7,278.32 |
| Food and Beverage | $2,110.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $222,865.86 | 2019-2025 | Pangea, Axsos, Pro |
| Synthes Gmbh | $45,680.19 | 2019-2025 | |
| Smith+Nephew, INC. | $700.30 | 2019-2025 | Q-Fix, Acufex, Evos |
| Hikma Pharmaceuticals USA | $305.33 | 2024 | Combogesic IV |
| Illuminoss Medical, INC. | $135.74 | 2024 | |
| Depuy Synthes Sales INC. | $124.80 | 2021-2023 | Na, Fibulink, Va-Lcp |
| Integra Lifesciences Corporation | $57.75 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Lowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.